Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Chanan-Khan

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 2011
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironmentJayakumar R Nair, Louise M Carlson, Chandana Koorella, et al.
British Journal of Haematology|February 19, 2015
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsKasyapa Chitta, Aneel Paulus, Sharoon Akhtar, et al.
Blood Advances|May 20, 2018
Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myelomaShehzad Niazi, Ryan D Frank, Mayank Sharma, et al.
Scientific Reports|June 7, 2016
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cellsXin Wang, Magdalena Mazurkiewicz, Ellin-Kristina Hillert, et al.
British Journal of Haematology|January 29, 2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugsAneel Paulus, Aisha Masood, Kena C Miller, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Leukemia & Lymphoma|May 30, 2009
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trialAsher Chanan-Khan, Kena C Miller, Laurie Musial, et al.
Leukemia & Lymphoma|November 8, 2011
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myelomaSikander Ailawadhi, Jeff Miecznikowski, Dan P Gaile, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 15, 2021
Awareness of myeloma care and the global impact of treatment: An international internet-based prospective studySikander Ailawadhi, Abhisek Swaika, Pooja Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 2011
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironmentJayakumar R Nair, Louise M Carlson, Chandana Koorella, et al.
British Journal of Haematology|February 19, 2015
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsKasyapa Chitta, Aneel Paulus, Sharoon Akhtar, et al.
Blood Advances|May 20, 2018
Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myelomaShehzad Niazi, Ryan D Frank, Mayank Sharma, et al.
Scientific Reports|June 7, 2016
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cellsXin Wang, Magdalena Mazurkiewicz, Ellin-Kristina Hillert, et al.
British Journal of Haematology|January 29, 2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugsAneel Paulus, Aisha Masood, Kena C Miller, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Leukemia & Lymphoma|May 30, 2009
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trialAsher Chanan-Khan, Kena C Miller, Laurie Musial, et al.
Leukemia & Lymphoma|November 8, 2011
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myelomaSikander Ailawadhi, Jeff Miecznikowski, Dan P Gaile, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 15, 2021
Awareness of myeloma care and the global impact of treatment: An international internet-based prospective studySikander Ailawadhi, Abhisek Swaika, Pooja Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 11